Pertuzumab
- Biologic
- PERJETA
Therapy management checklist
Screening, baseline and ongoing monitoring with the label's stated frequency, hold and discontinue criteria, and counseling points, each quoted from the FDA label.
Loading the therapy management checklist…
Storage and cold chain
Pertuzumab: storage and handling
- Refrigerate
- Yes, as the label states
Label statement
Store vials refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton until time of use to protect from light.
- Freezing
- Do not freeze
Label statement
Do not freeze.
- Room temperature
- No allowance stated
- Back into the refrigerator
- Not addressed
- Light
- Protect from light
Label statement
Store vials refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton until time of use to protect from light.
- Shaking
- Do not shake
Label statement
Do not shake.
All storage statements on the label (3)
- Store vials refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton until time of use to protect from light.
- Do not freeze.
- Do not shake.
FDA label version 27, effective April 30, 2026. DailyMed
Dosing and titration calendar
Built only from the schedules the label states (loading, titration, day schedules, cycles and weight bands). Steps the label states in words the calendar cannot place are shown, not guessed.
Loading dosing schedules…
Biosimilars
Perjeta: 1 licensed biosimilar product, 1 interchangeable (FDA Purple Book). Compare presentations and dates
Medicare Part D coverage
No Part D formulary in the CMS files (2026Q3) lists this drug. It may be covered under Part B or not covered.
Patient assistance
No manufacturer program page is listed for this drug yet.
Independent foundations and the full directory (checked 2026-11-06). Eligibility and amounts are set by each program; open its page for them.
For licensed clinicians. Use with clinical judgment. Statements are quoted from the FDA label; confirm against the label for the product you are using.